| Literature DB >> 20969809 |
Eva Ekvall Hansson1, Malin Jönsson-Lundgren, Anne-Marie Ronnheden, Eva Sörensson, Asa Bjärnung, Leif E Dahlberg.
Abstract
BACKGROUND: Osteoarthritis (OA) is a degenerative disease, considered to be one of the major public health problems. Research suggests that patient education is feasible and valuable for achieving improvements in quality of life, in function, well-being and improved coping. Since 1994, Primary Health Care in Malmö has used a patient education programme directed towards OA. The aim of this study was to evaluate the effects of this education programme for patients with OA in primary health care in terms of self-efficacy, function and self-perceived health.Entities:
Mesh:
Year: 2010 PMID: 20969809 PMCID: PMC2987970 DOI: 10.1186/1471-2474-11-244
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
The patient education programme for osteoarthritis (PEPOA)
| Session | Content |
|---|---|
| First session | Physiotherapist and occupational therapist at the same time. Information about anatomy, about physiology of pain and coping with pain. Try cold and heat. Brainstorming about what the participants finds hard to do. |
| Second session | Physiotherapist. Information about exercise and physical activity. Practical demonstration of home-training exercises for the lower extremity. Demonstration of different kinds of orthopaedic aids for the lower extremity. |
| Third session | Orthopaedic specialist, nurse and nutritionist. Information about OA and current research. Information about medications. Information about appropriate diet. |
| Fourth session | Occupational therapist. Ergonomics and practical instructions about equipment and technical aids. Feedback to the brainstorming from session one. |
| Fifth session | Occupational therapist. Information about surgery of the hand, demonstration of orthopaedic aids for hands. Try out treatment with hot paraffin. Practical demonstration of home training exercises for the hand. |
The programme lasted for five weeks, with group sessions once a week, three hours for each session.
Baseline data for the study group, mean values, range and standard deviation (SD).
| Intervention | Control | ||||||
|---|---|---|---|---|---|---|---|
| n = 61 | n = 53 | ||||||
| BMI | 28.31 | 18.59-46.72 | 5.42 | 27.82 | 20.61-43.58 | 5.00 | 0.41 |
| Age | 62 | 42-81 | 9.43 | 63 | 41-84 | 9.51 | 0.83 |
| ASES-Pain | 57.47 | 10-98 | 20.49 | 54.33 | 10-100 | 23.62 | 0.33 |
| ASES-Function | 74.81 | 34-100 | 17.37 | 73.59 | 28-100 | 19.88 | 0.35 |
| ASES-Other symtoms | 66.78 | 15-100 | 19.43 | 67.31 | 17-100 | 23.68 | 0.12 |
| EQ5D-index | 0.58 | -0.022-0.79 | 0.25 | 0.56 | -0.13-1.01 | 0.30 | 0.14 |
| EQ5D-VAS | 63.52 | 0-100 | 21.81 | 65.73 | 20-100 | 22.19 | 0.62 |
| GAT total | 22.87 | 12-79.39 | 10.09 | 24.67 | 14-47.81 | 7.83 | 0.45 |
| GAT 1 | 7.89 | 1.81-39.59 | 5.52 | 7.91 | 3.62-18.01 | 3.29 | 0.47 |
| GAT 2 | 4.28 | 2.00-14.02 | 2.48 | 5.12 | 2.03-16.19 | 2.68 | 0.18 |
| GAT 3 | 10.49 | 5.38-28.82 | 3.72 | 11.90 | 5.41-28.79 | 4.58 | 0.19 |
| SOLEO (sec) | 33.55 | 0-60 | 22.02 | 35.71 | 0-60 | 23.00 | 0.60 |
| SOLEC (sec) | 6.18 | 0-30 | 6.31 | 6.82 | 0-30 | 7.09 | 0.58 |
| One-legged jump (cm) | 34.78 | 0-147 | 33.29 | 33.11 | 0-98 | 29.90 | 0.63 |
| One-legged raising (as many times as possible) | 9.00 | 0-31 | 8.89 | 12.03 | 0-48 | 12.73 | 0.83 |
| Bipedal raising (as many times as possible) | 15.00 | 3-50 | 12.10 | 13.10 | 0-30 | 8.40 | 0.61 |
| OA location* (number) | 3/21/21/16 | 2/18/16/17 | 0.71 | ||||
| Smokers (number) | 5 | 9 | 0.36 | ||||
| BMI groups 20-25/25-30/>30 (number) | 22/24/16 | 18/20/15 | 0.41 | ||||
* hip/knee/hand/more than one location.
Figure 1Flowchart of the study.
Mean changes from baseline, mean difference, 95% CI of difference, p-value.
| Intervention n = 61 | Control n = 53 | ||||
|---|---|---|---|---|---|
| mean change | mean change | diff | (CI) | p | |
| GAT total (points) | -1.52 | -1.69 | 0.17 | (-2.56 to 2.91) | 0.90 |
| GAT 1 (points) | -0.88 | -0.06 | 0.82 | (-2.43 to 0.79) | 0.32 |
| GAT 2 (points) | -0.61 | -1.24 | 0.63 | (-0.21 to 1.46) | 0.14 |
| GAT 3 (points) | 0.10 | -0.53 | 0.63 | (-0.69 to 2.07) | 0.31 |
| SOLEO (sec) | -1.35 | -3.94 | 2.59 | (-3.29 to 8.47) | 0.38 |
| SOLEC (sec) | 0.57 | -1.13 | 1.17 | (0.33 to 3.06) | |
| One-legged jump (cm) | -4.07 | -7.55 | 3.48 | (-7.08 to 14.04) | 0.51 |
| One-legged rising (times) | 2.33 | -1.08 | 3.41 | (-2.07 to 8.89) | 0.22 |
| Bipedal rising (times) | 1.30 | -3.91 | 5.19 | (-0.53 to 10.92) | 0.10 |
| ASES-Pain | 4.94 | 4.08 | 0.86 | (-6.72 to 8.44) | 0.82 |
| ASES-Function | 3.89 | -0.39 | 4.25 | (-1.42 to 10.07) | 0.14 |
| ASES-Other symptoms | 4.85 | 0.92 | 3.93 | (-2.41 to 10.27) | 0.23 |
| EQ5D-index | 0.07 | 0.00 | 0.07 | (-0.02 to 10.17) | 0.17 |
| EQ5D-VAS | 5.59 | 1.18 | 3.73 | (-3.01 to 10.47) | |
In GAT, decrease means improvement, in all other tests, increase means improvement.
Proportion of levels 1, 2 and 3 in EQ5D by dimension and group at baseline and at test after 6 months.
| EQ5D dimensions | Intervention baseline/6 months % | Control baseline/6 months % | p | |
|---|---|---|---|---|
| Mobility | Level 1* | 46/54 | 47/47 | |
| Level 2 | 54/46 | 53/53 | ||
| Level 3 | 0/0 | 0/0 | ||
| Self-care | Level 1 | 90/89 | 89/81 | |
| Level 2 | 10/11 | 9/17 | ||
| Level 3 | 0/0 | 2/2 | ||
| Usual activities | Level 1 | 57/76 | 60/58 | |
| Level 2 | 41/22 | 34/40 | ||
| Level 3 | 2/0 | 6/2 | ||
| Pain/discomfort | Level 1 | 0/3 | 5/6 | |
| Level 2 | 84/84 | 78/73 | ||
| Level 3 | 16/13 | 17/21 | ||
| Anxiety/depression | Level 1 | 40/57 | 37/41 | |
| Level 2 | 60/43 | 53/50 | ||
| Level 3 | 0/0 | 10/9 |
P-values for the difference in change between baseline and 6 months, between the two groups.
*Level 1 indicates no problems, level 2 indicates some problems and level 3 indicates extreme problems.